On Thursday 30th of July, we announced our H1 2026 results. An accompanying webcast for investors and analysts took place at 14:00 CET. UCB HY26 Documents Earning Call Slides space Earnings Call Transcript space Press release Half Year Report 26 - EN space Half Year Report 26 - FR space Half Year Report 26 - NL Space Excel File HY26 Pipeline Overview H1 space Facts and Figures HY26 space Clinical Trials appendix HY26 UCB FY25 Documents Press release FY25 Earnings Call - Presentation FY25 Earnings Call - Replay FY25 Earnings Call - Transcript Full Year Report 2025 Scientific Presentations, Abstracts, Posters, and Publications for Shareholders, Investors, and other Capital Market Participants Only The following documents are specifically for shareholders, investors, and other capital market participants. The webpages are not intended for members of the general public. Bimekizumab Rozanolixizumab Zilucoplan Corporate Governance Documents Also find more information on the dedicated section of our website. Governance charter Dealing code Code of conduct UCB Reports Archive ENGFRNL Title Year Format Download Integrated Annual Report 2025 PDF Download Integrated Annual Report 2025 xbri Download Half-Year Report 2025 PDF Download Integrated Annual Report 2024 PDF Download Integrated Annual Report 2024 ESEF Download View more Investor Relations Team Please reach us via investor-relations@ucb.com or a specific team member: Yvonne NaughtonHead of Investor Relations +44-175-344 7521Yvonne.Naughton@ucb.com Sahar YazdianInvestor Relations Lead Lead +32 2 559 9137Sahar.Yazdian@ucb.com Diyana MishuInvestor Relations Manager +32 2 559 7446Diyana.Mishu@ucb.com Yifei (Faye) WuAssistant Assistant Assistant +32 2 559 9087Yifei.Wu@ucb.com Book a virtual meeting Send us feedback
